Cardiology and Therapy最新文献

筛选
英文 中文
The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt. 心房颤动登记(FLOW-AF):埃及的患者特征、治疗模式和结果。
IF 3
Cardiology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-03-21 DOI: 10.1007/s40119-025-00400-0
Mohamed Sobhy, Magdy Abdelhamid, Adel Mohamed El Etriby, Mohamed Fathy Soliman Gamaleldin, Ahmed Mohamed Helmy Youssef, Natasha Khalife, Hany Ragy, Ashraf Reda, Maichel Sobhy, Mostafa Nawar
{"title":"The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt.","authors":"Mohamed Sobhy, Magdy Abdelhamid, Adel Mohamed El Etriby, Mohamed Fathy Soliman Gamaleldin, Ahmed Mohamed Helmy Youssef, Natasha Khalife, Hany Ragy, Ashraf Reda, Maichel Sobhy, Mostafa Nawar","doi":"10.1007/s40119-025-00400-0","DOIUrl":"10.1007/s40119-025-00400-0","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world data on atrial fibrillation (AF) in the Middle East and North Africa (MENA) region, including Egypt, are sparse. The aim of the FLOW-AF registry was to evaluate the characteristics, treatment patterns, and clinical and economic outcomes of newly diagnosed non-valvular atrial fibrillation (NVAF) patients within the MENA region, including Egypt.</p><p><strong>Methods: </strong>This multicenter, prospective, observational registry enrolled newly diagnosed patients with NVAF from January 2020 to December 2022 at eight private-sector healthcare centers in Egypt. Data were collected at enrollment (baseline), and then at 6-month and 12-month follow-up. Baseline data included demographics, AF characteristics, medical history, and antithrombotic treatment patterns. Follow-up data included clinical events, healthcare resource utilization, and related costs.</p><p><strong>Results: </strong>A total of 723 patients were enrolled. Overall, 51.87% were females, and the mean age was 61.9 years. All patients attended the private health sector. The mean (standard deviation) CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED risk scores were 2.37 (1.55) and 1.46 (1.18), respectively. Non-vitamin K antagonist oral anticoagulants (62.52%), vitamin K antagonists (22.28%), and antiplatelet therapy (9.85%) were among the prescribed treatments. Rates of transient ischemic attack and all-cause mortality were 2.64% and 0.83%, respectively; all other outcomes (stroke, bleeding, myocardial infarction, systemic embolism) occurred at a rate of ≤ 0.41%. Antithrombotic medications were the major contributors to per-patient total yearly cost (USD 381.2).</p><p><strong>Conclusions: </strong>The FLOW-AF study showed that patients with NVAF in Egypt are younger and exhibit lower mean baseline CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED scores compared to Western and other Eastern regions. Additional research, including a broader study population with a longer follow-up, is essential to comprehensively assess the characteristics and outcomes of the NVAF population in Egypt.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":"161-182"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of the Fixed-Dose Combination of Atorvastatin/Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients with Type 2 Diabetes and Dyslipidemia. 阿托伐他汀/非诺贝特固定剂量联合用药与阿托伐他汀对2型糖尿病合并血脂异常患者血脂的疗效和安全性
IF 3
Cardiology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1007/s40119-025-00410-y
Francisco G Padilla-Padilla, Lina N Ruiz-Bernes, Luis M Román-Pintos, Juan A Peraza-Zaldívar, José G Sander-Padilla, Laura A Lugo-Sánchez, Kevin F Rios-Brito, María M Arguedas-Núñez, Diana Flores-Huanosta, Jorge González-Canudas
{"title":"Efficacy and Safety of the Fixed-Dose Combination of Atorvastatin/Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients with Type 2 Diabetes and Dyslipidemia.","authors":"Francisco G Padilla-Padilla, Lina N Ruiz-Bernes, Luis M Román-Pintos, Juan A Peraza-Zaldívar, José G Sander-Padilla, Laura A Lugo-Sánchez, Kevin F Rios-Brito, María M Arguedas-Núñez, Diana Flores-Huanosta, Jorge González-Canudas","doi":"10.1007/s40119-025-00410-y","DOIUrl":"10.1007/s40119-025-00410-y","url":null,"abstract":"<p><strong>Introduction: </strong>In dyslipidemia associated with type 2 diabetes (T2DM), elevated triglycerides (TG), increased low-density lipoprotein cholesterol (LDL-C), and decreased high-density lipoprotein cholesterol (HDL-C) levels are commonly found, resulting in a high prevalence of mixed dyslipidemia among patients with T2DM. Therefore, the combination therapy of atorvastatin/fenofibrate may be useful for simplifying pharmacological regimens, enhancing adherence, and requiring fewer doses of each drug to achieve the target, which decreases the number of adverse events.</p><p><strong>Methods: </strong>We conducted a randomized multicenter, double-blind clinical trial of patients with T2DM and mixed dyslipidemia to evaluate the magnitude of change in lipid profile with a fixed-dose combination (FDC) therapy group of atorvastatin 20 mg/fenofibrate 160 mg (G_FDC) versus atorvastatin 20 mg monotherapy group (G_M), both oral route, one tablet every 24 h. The magnitude of change in the lipid profile at 2 and 4 months was compared within each group and between groups using the analysis of variance (ANOVA) test. A p value ≤ 0.05 was considered statistically significant.</p><p><strong>Results: </strong>A total of 76 patients were included (38 per group), with an age of 56.7 ± 10.2 years, and 56.6% were women. The values at 4 months for G_FDC vs. G_M were as follow: TG mg/dL (-144.3 vs. -64.0, p = 0.004), TG percentage change (%C) (-47.9 vs. -33.1, p = 0.007); LDL-C mg/dL (-50.5 vs. -51.7, p = 0.784), LDL-C %C (-42.5 vs. -45.6, p = 0.899). The percentage of patients who achieved the targets for triglycerides (TG) was 56.7% compared to 43.8% (p = 0.309), while for LDL-C, it was 73.3% compared to 78.1% (p = 0.660). Finally, the predictive cardiovascular risk indices (∆ of change) showed a TG/HDL index of -3.9 ± 4.6 vs. -1.5 ± 2.9 (p = 0.015) and a Tg/glucose index of -0.7 ± 0.5 vs. -0.3 ± 0.4 (p = 0.003).</p><p><strong>Conclusion: </strong>The FDC therapy of atorvastatin 20 mg/fenofibrate 160 mg achieved a greater percentage reduction in lipid profile than atorvastatin alone. No differences in adverse events were observed between the groups.</p><p><strong>Clinical trials registration: </strong>ClinicalTrials.gov No. NCT04882293, registration date: February 28, 2022.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":"297-314"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impella Versus VA-ECMO for Patients with Cardiogenic Shock: Preliminary Cost-Effectiveness Analysis in the Italian Context. Impella vs . VA-ECMO治疗心源性休克:意大利初步成本-效果分析
IF 3
Cardiology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-03-28 DOI: 10.1007/s40119-025-00404-w
Carla Rognoni, Vittoria Ardito, Dario La Fauci, Marina Pieri, Anna Mara Scandroglio, Rosanna Tarricone
{"title":"Impella Versus VA-ECMO for Patients with Cardiogenic Shock: Preliminary Cost-Effectiveness Analysis in the Italian Context.","authors":"Carla Rognoni, Vittoria Ardito, Dario La Fauci, Marina Pieri, Anna Mara Scandroglio, Rosanna Tarricone","doi":"10.1007/s40119-025-00404-w","DOIUrl":"10.1007/s40119-025-00404-w","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiogenic shock (CS) is a life-threatening failure of the heart to supply adequate blood, requiring immediate treatment. Although nowadays Impella<sup>®</sup> heart pumps and veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) are both widely employed in routine clinical practice for the management of patients with CS, extensive comparative information on their cost-effectiveness is lacking. The aim of the present study was to conduct a cost-effectiveness analysis comparing Impella to VA-ECMO in patients with CS from the National Healthcare Service (NHS) perspective in Italy. A secondary objective was to compare costs from both NHS and hospital perspectives.</p><p><strong>Methods: </strong>A Markov model projected, on a lifetime horizon, life years (LYs), quality-adjusted life years (QALYs), and costs associated with Impella and VA-ECMO. Costs from the NHS perspective were estimated mainly through Italian reimbursement rates, while hospital costs were derived from a clinical center in Italy.</p><p><strong>Results: </strong>From an NHS perspective, Impella showed lower costs and better life expectancy and patients' quality of life (€50,303, 1.544 LYs, 0.905 QALYs) compared to VA-ECMO (€76,795, 1.391 LYs, 0.784 QALYs). DRG overall reimbursements for Impella (€49,998) do not completely cover the hospital costs and the cost for the technology (€57,770). Conversely, the hospital cost for the strategy VA-ECMO (€52,190) is lower than the NHS overall reimbursements (€76,790).</p><p><strong>Conclusions: </strong>Our analysis suggests that Impella may be cost-saving over VA-ECMO, while also providing better health outcomes for patients with CS; however, discrepancies in costs and reimbursement rates were observed, likely due to variability in patient care and hospital resource utilization. Future real-world studies are needed to confirm these findings, but decision-makers can use this data as an initial reference for health technology assessments in Italy.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":"183-198"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study. 马伐卡坦对中国梗阻性肥厚性心肌病患者超声心动图特征的影响:来自EXPLORER-CN研究的结果
IF 3
Cardiology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-29 DOI: 10.1007/s40119-025-00409-5
Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian'an Wang, Yunqi Shi, Daoquan Peng, Ping Yang, Wei Ma, Fang Wang, Wei Jin, Xiang Cheng, Yu-Mao Chen, Yue Zhong, Yu Chen Barrett, Jing Zheng, Shuyang Zhang
{"title":"Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study.","authors":"Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian'an Wang, Yunqi Shi, Daoquan Peng, Ping Yang, Wei Ma, Fang Wang, Wei Jin, Xiang Cheng, Yu-Mao Chen, Yue Zhong, Yu Chen Barrett, Jing Zheng, Shuyang Zhang","doi":"10.1007/s40119-025-00409-5","DOIUrl":"10.1007/s40119-025-00409-5","url":null,"abstract":"<p><strong>Introduction: </strong>Mavacamten, a cardiac myosin inhibitor, has demonstrated positive outcomes in left ventricular outflow tract (LVOT) gradient reduction and improvements of symptoms and function in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in EXPLORER-CN. This exploratory analysis aimed to evaluate the effect of mavacamten on echocardiographic measures of cardiac structure and function and its relationship with other clinical biomarkers.</p><p><strong>Methods: </strong>Key echocardiographic parameters acquired over 30 weeks from 81 patients (n = 54 on mavacamten and n = 27 on placebo) were assessed in a central laboratory.</p><p><strong>Results: </strong>At 30 weeks, greater improvements in measures of diastolic function were observed with mavacamten versus placebo, including lateral E/e' (least-squares mean [LSM] change from baseline [CFB] - 5.1 vs. 0.6; between-group LSM difference - 5.7; 95% confidence interval [CI] - 7.6 to - 3.7), septal E/e' (LSM CFB - 6.0 vs. - 0.3; between-group LSM difference - 5.7; 95% CI - 7.8 to - 3.7), and left atrial volume index (LAVI) (LSM CFB - 11.7 vs. - 3.5 ml/m<sup>2</sup>; between-group LSM difference - 8.2; 95% CI - 12.0 to - 4.4) (nominal p < 0.001 for all). Twelve patients (23.1%) treated with mavacamten had complete resolution of mitral valve systolic anterior motion (SAM) versus two patients (7.4%) receiving placebo. Among mavacamten-treated patients, reductions in resting and Valsalva LVOT gradients, left ventricular (LV) mass index, LAVI, and lateral and septal E/e' were associated with reduced N-terminal pro-B-type natriuretic peptide levels (nominal p < 0.0001 for all). In the mavacamten group, reductions in LVOT gradients and LV end-diastolic interventricular septal thickness were associated with improved patient-reported Kansas City Cardiomyopathy Questionnaire Overall Summary Score (nominal p < 0.05 for all).</p><p><strong>Conclusions: </strong>Clinically meaningful improvements were evident in Chinese patients treated with mavacamten compared with placebo in several hallmarks of obstructive HCM, including measures of LV diastolic function, SAM, and LVOT gradient. These results add further evidence to support the positive effects of mavacamten in cardiac remodeling.</p><p><strong>Registration: </strong>ClinicalTrials.gov identifier: NCT05174416.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":"267-282"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stressful Life Events and Heart Failure: A Mixed-Method Study to Analyze the Patient's Perspective. 压力生活事件和心力衰竭:一项混合方法研究来分析患者的观点。
IF 3
Cardiology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-17 DOI: 10.1007/s40119-025-00406-8
Dina Di Giacomo, Eleonora Cilli, Federica Guerra, Francesco Barbati, Renata Petroni, Luigi Sciarra, Silvio Romano
{"title":"Stressful Life Events and Heart Failure: A Mixed-Method Study to Analyze the Patient's Perspective.","authors":"Dina Di Giacomo, Eleonora Cilli, Federica Guerra, Francesco Barbati, Renata Petroni, Luigi Sciarra, Silvio Romano","doi":"10.1007/s40119-025-00406-8","DOIUrl":"10.1007/s40119-025-00406-8","url":null,"abstract":"<p><strong>Introduction: </strong>The challenge in heart failure medical practice is to address the clinical and laboratory method integrations for the shared decision-making process in caring for patients and families. Furthermore, stressful life events may worsen outcomes in patients with heart failure. This study aimed to explore patient perceptions regarding cardiac care analyzing the individual needs and features of adverse life event experiences.</p><p><strong>Methods: </strong>A mixed-methods design was used in this study. This quantitative research focuses on clinical (medical and psychological) data. Giorgi's phenomenological method was applied to the interview analysis.</p><p><strong>Results: </strong>Qualitative analyses highlighted the role of patient-engagement strategies powered by cardiologists in a personalized approach that favors adherence to complex medical therapies. Active patient involvement and associated engagement based on cardiologists' confidence are focal points for facilitating management-therapy strategies to improve outcomes and reduce the perception of the frailty burden. The quality of therapeutic relationships with cardiologists is a key protective factor for accurate risk stratification and therapeutic decision-making in patients, addressing the potential benefits of therapeutic interventions.</p><p><strong>Conclusions: </strong>In conclusion, the engaged patient contributes to more efficient cardiological care and the personalized patient-centered approach leads to the more efficient 'cure and care' clinical model. In adverse life events, acute psychological and physiological stress responses intensify detrimental outcomes for patients with cardiovascular disorders. Integrative management of physical risks and mental resilience factors in the development of cardiac disease appears to be strategic for patients with a positive quality of life (QoL) and clinical management of heart failure (HF).</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":"199-217"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ACE Inhibitors and Angiotensin Receptor Blockers for the Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus. ACE抑制剂和血管紧张素受体阻滞剂预防心血管疾病:来自2024年埃及心脏病专家共识的建议
IF 3
Cardiology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-02-18 DOI: 10.1007/s40119-025-00399-4
Neil Poulter
{"title":"ACE Inhibitors and Angiotensin Receptor Blockers for the Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus.","authors":"Neil Poulter","doi":"10.1007/s40119-025-00399-4","DOIUrl":"10.1007/s40119-025-00399-4","url":null,"abstract":"","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":"117-121"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ACEi and ARBs as Primary Prevention of Cancer Therapy-Related Cardiomyopathy in Patients Undergoing Chemotherapy with Anthracyclines: A Systematic Review and Meta-Analysis. ACEi和ARBs作为蒽环类药物化疗患者癌症治疗相关心肌病的一级预防:系统回顾和荟萃分析
IF 3
Cardiology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-03-16 DOI: 10.1007/s40119-025-00401-z
Wissam Harmouch, Ravi Thakker, Alexander Dang, Abdelazeem Mohamed Etewa, Krishna Suthar, Salim Hayek, Wissam Khalife, Ayman Elbadawi
{"title":"ACEi and ARBs as Primary Prevention of Cancer Therapy-Related Cardiomyopathy in Patients Undergoing Chemotherapy with Anthracyclines: A Systematic Review and Meta-Analysis.","authors":"Wissam Harmouch, Ravi Thakker, Alexander Dang, Abdelazeem Mohamed Etewa, Krishna Suthar, Salim Hayek, Wissam Khalife, Ayman Elbadawi","doi":"10.1007/s40119-025-00401-z","DOIUrl":"10.1007/s40119-025-00401-z","url":null,"abstract":"<p><strong>Introduction: </strong>Anthracyclines treat a myriad of malignancies; however, they are known to lead to cancer therapy-related cardiomyopathy (CTRC). Randomized controlled trials (RCTs) evaluating the role of angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) in primary prevention of CTRC have yielded mixed results.</p><p><strong>Methods: </strong>A systematic search of MEDLINE, Cochrane, and Scopus databases was performed to identify RCTs that evaluated outcomes in patients receiving anthracyclines and ACEi or ARBs versus control. The primary outcome was occurrence of CTRC. All data were pooled using a random-effects model.</p><p><strong>Results: </strong>The final analysis included 10 RCTs, with 1049 patients assessed. The weighted follow-up period was 16.8 months. The average age was 43.2 years and 90% were female. Breast cancer (80%) and lymphomas (13%) were the most common malignancies. There was no statistically significant difference between the groups with regards to occurrence of CTRC (16% vs 24%; risk ratio (RR) 0.67, 95% confidence interval (CI) [0.31, 1.45]). Compared with control, ACEi/ARBs were associated with favorable absolute changes in left ventricular ejection fraction (LVEF) (standardized mean difference (SMD) + 1.20%, 95% CI [0.40, 2.00]), left ventricular end-diastolic volume (SMD - 0.36 mL, 95% CI [- 0.66, - 0.06]), and left ventricular end-systolic volume (SMD - 1.04 mL, 95% CI [- 1.79, - 0.29]). There was also a lower risk of arrhythmias in the ACEi/ARBs group compared to control (1.6% vs 8.0%; RR 0.30, 95% CI [0.10, 0.94]), but no difference in all-cause mortality (2.8% vs 3.2%; RR 0.82, 95% CI [0.26, 2.61]), or heart failure (1.2% vs 7.1%; RR 0.40, 95% CI [0.03, 4.54]).</p><p><strong>Conclusions: </strong>ACEi/ARBs therapy was not associated with a reduction in CTRC among patients with cancer receiving anthracyclines. However, there were favorable changes in LVEF and left ventricular remodeling with ACEi/ARBs therapy. Further large-scale studies are needed to better understand the potential role of ACEi/ARBs in preventing long-term cardiotoxicity.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":"141-159"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arterial Hypertension and Associated Risk Factors in Kazakhstan: An Analysis of Blood Pressure Screening Results from May Measurement Month 2021-2023. 哈萨克斯坦动脉高血压及相关危险因素:2021-2023年5月测量月血压筛查结果分析
IF 3
Cardiology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-29 DOI: 10.1007/s40119-025-00412-w
Dilyara M Mukhtarkhanova, Gulnara A Junusbekova, Meiramgul K Tundybayeva, Tatyana N Leonovich, Lyazat S Baglanova, Eldar M Ismailov, Sabina B Samitova
{"title":"Arterial Hypertension and Associated Risk Factors in Kazakhstan: An Analysis of Blood Pressure Screening Results from May Measurement Month 2021-2023.","authors":"Dilyara M Mukhtarkhanova, Gulnara A Junusbekova, Meiramgul K Tundybayeva, Tatyana N Leonovich, Lyazat S Baglanova, Eldar M Ismailov, Sabina B Samitova","doi":"10.1007/s40119-025-00412-w","DOIUrl":"10.1007/s40119-025-00412-w","url":null,"abstract":"<p><strong>Introduction: </strong>May Measurement Month (MMM) is a global campaign with the aim to improve awareness of arterial hypertension (AH). Kazakhstan participated in the campaign in 2021, 2022 and 2023.</p><p><strong>Methods: </strong>During the cross-sectional 2021-2023 MMM surveys, volunteer adults (≥ 18 years) from cities in Kazakhstan had their blood pressure (BP) measured three times in a seated position, and received a questionnaire on their demographics, lifestyle and medical history. In those not receiving antihypertensive treatment, AH was defined as a mean systolic and/or diastolic BP ≥ 140/90 mmHg.</p><p><strong>Results: </strong>A total of 8231 individuals took part in the survey, with 1805 participants in 2021, 2410 participants in 2022 and 4016 participants in 2023. The prevalence of AH was estimated to be 37% in 2021 and 45% in 2022 and 2023. Of those identified as having AH, 51-70% were aware that they had the condition. Among those who were aware that they had AH, 68-91% were receiving antihypertensive therapy. However, 70-82% of treated participants were only receiving one to two drugs. BP was controlled to < 140/90 mmHg in 43-50% of treated participants and to < 130/80 mmHg in 15-16%.</p><p><strong>Conclusion: </strong>The 2021, 2022 and 2023 MMM campaigns showed that high proportion of AH, a low level of AH awareness and inadequate BP control in Kazakhstan. Programs are needed to increase awareness of the risks of high BP and to improve the diagnosis and effective treatment of AH.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":"283-296"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Defibrillation Threshold Testing After ICD Implantation in Patients with Chronic Kidney Disease. 慢性肾病患者ICD植入后除颤阈值测定。
IF 3
Cardiology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-23 DOI: 10.1007/s40119-025-00403-x
Rohit J Timal, Lano Osman, Joris I Rotmans, Marianne Bootsma, Bart Mertens, Martin J Schalij, Ton J Rabelink, J Wouter Jukema
{"title":"Defibrillation Threshold Testing After ICD Implantation in Patients with Chronic Kidney Disease.","authors":"Rohit J Timal, Lano Osman, Joris I Rotmans, Marianne Bootsma, Bart Mertens, Martin J Schalij, Ton J Rabelink, J Wouter Jukema","doi":"10.1007/s40119-025-00403-x","DOIUrl":"10.1007/s40119-025-00403-x","url":null,"abstract":"<p><strong>Introduction: </strong>Routine defibrillation threshold (DFT) testing at the time of implantable cardioverter-defibrillator (ICD) implantation is no longer recommended because testing did not improve shock efficacy or reduce arrhythmic death. However, patients with severe chronic kidney disease (CKD) were not included in these trials and might benefit from DFT testing. International guidelines shed no light on the subject of the effect of kidney function on DFT testing in patients with CKD.</p><p><strong>Methods: </strong>In this retrospective study, we aimed to identify the success and safety of DFT in patients with CKD stages 1-5 (ages 55-80 years) undergoing primary transvenous ICD implantation.</p><p><strong>Results: </strong>A total of 451 patients were stratified into three groups based on kidney function: group 1 with CKD stage 1-2 (n = 294), group 2 with CKD stage 3-4 (n = 90), and group 3 with CKD stage 5 (n = 67). Ventricular fibrillation was induced 827 times. The median number of threshold testing per patient was two (interquartile range 1-2; range 1-7). No evidence of between CKD-group differences in ICD defibrillation success rates could be found when using all patient attempts, regardless of correction for energy levels (p = 0.262). DFT-related complications occurred in 16 patients (3.5%), predominantly hypoxemia due to hypoventilation (1.6%) and atrial arrhythmias. Five patients (1.1%) underwent ICD or lead revision following abnormal DFT test results.</p><p><strong>Conclusions: </strong>We did not demonstrate a correlation between CKD and increased DFT or an increased rate of inadequate defibrillation safety margin. DFT testing is feasible with a low risk of serious complications in patients with moderate and advanced CKD when clinically deemed necessary. DFT testing is not routinely required in patients with (advanced) CKD.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":"219-230"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of Screening Fetal Echocardiograms Following Normal Level II Ultrasounds in Fetuses with Siblings with Congenital Heart Disease. 在兄弟姐妹患有先天性心脏病的胎儿中,正常II级超声检查后胎儿超声心动图筛查的应用。
IF 3
Cardiology and Therapy Pub Date : 2025-05-31 DOI: 10.1007/s40119-025-00419-3
Kacy Taylor, Casey Lovelace, Erin Van Pelt, Oluseyi Ogunleye, Karen Texter, Clifford L Cua
{"title":"Utility of Screening Fetal Echocardiograms Following Normal Level II Ultrasounds in Fetuses with Siblings with Congenital Heart Disease.","authors":"Kacy Taylor, Casey Lovelace, Erin Van Pelt, Oluseyi Ogunleye, Karen Texter, Clifford L Cua","doi":"10.1007/s40119-025-00419-3","DOIUrl":"https://doi.org/10.1007/s40119-025-00419-3","url":null,"abstract":"<p><strong>Introduction: </strong>In pregnancies when congenital heart disease (CHD) is present in siblings, fetal echocardiograms (F-echo) are recommended, regardless if there was a prior level II ultrasound (LII-US) that was normal. The goal of this study was to evaluate if any diagnosis of a critical congenital heart disease (CHD) was missed in a fetus who had a sibling with CHD, when a normal LII-US was documented.</p><p><strong>Methods: </strong>Retrospective chart review of all F-echo where the indication was sibling with CHD between January 1, 2019 and December 31, 2023 was performed. Fetuses were included if they had a LII-US that was read as normal and had a F-echo. Critical CHD was defined as CHD requiring catheterization or surgical intervention < 1 month of age.</p><p><strong>Results: </strong>A total of 187 F-echo on fetuses who had a sibling with CHD were evaluated, of which 113 met inclusion criteria. LII-US was performed at 21.1 ± 3.3 weeks gestational age and F-echo was performed at 25.4 ± 3.1 weeks gestational age. No patient with a normal LII-US had a diagnosis of a critical CHD by F-echo (negative predictive value = 100%). Six patients that had a negative LII-US were diagnosed with non-critical CHD or cardiac issues postnatally (negative predictive value = 94.7%). F-echo correctly diagnosed two of the six missed LII-US CHD.</p><p><strong>Conclusion: </strong>Critical CHD was not missed with a normal LII-US in this at-risk population. F-echo also missed the majority of CHD when a LII-US was read as normal. The cost/benefit of screening F-echo in fetuses with siblings with CHD should be evaluated if a normal LII-US has been performed. Larger studies are needed to determine if these findings remain consistent.</p>","PeriodicalId":9561,"journal":{"name":"Cardiology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信